252 related articles for article (PubMed ID: 34115024)
21. Apixaban Dosing Patterns Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation Receiving Dialysis: A Retrospective Cohort Study.
Wetmore JB; Weinhandl ED; Yan H; Reyes JL; Herzog CA; Roetker NS
Am J Kidney Dis; 2022 Nov; 80(5):569-579.e1. PubMed ID: 35469965
[TBL] [Abstract][Full Text] [Related]
22. Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study.
Rutherford OW; Jonasson C; Ghanima W; Söderdahl F; Halvorsen S
Eur Heart J Cardiovasc Pharmacother; 2020 Apr; 6(2):75-85. PubMed ID: 31942972
[TBL] [Abstract][Full Text] [Related]
23. Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation.
Bahit MC; Lopes RD; Wojdyla DM; Held C; Hanna M; Vinereanu D; Hylek EM; Verheugt F; Goto S; Alexander JH; Wallentin L; Granger CB
Heart; 2017 Apr; 103(8):623-628. PubMed ID: 27798052
[TBL] [Abstract][Full Text] [Related]
24. Safety outcomes of apixaban in patients with nonvalvular atrial fibrillation and severe renal impairment.
Jones MJ; Eudaley ST; Moye RA; Hodge TA; Nesbit RM; Franks AS
J Thromb Thrombolysis; 2020 Aug; 50(2):330-336. PubMed ID: 31902123
[TBL] [Abstract][Full Text] [Related]
25. Comparison of the Safety and Effectiveness of Four Direct Oral Anticoagulants in Japanese Patients with Nonvalvular Atrial Fibrillation Using Real-World Data.
Enomoto A; Mano Y; Kawano Y; Nishikawa T; Aoyama T; Sasaki Y; Nagata M; Takahashi H
Biol Pharm Bull; 2021; 44(9):1294-1302. PubMed ID: 34471057
[TBL] [Abstract][Full Text] [Related]
26. Persistence on apixaban in atrial fibrillation patients: a retrospective multicentre study.
Verdecchia P; D'Onofrio A; Russo V; Fedele F; Adamo F; Benedetti G; Ferrante F; Lodigiani C; Paciullo F; Aita A; Bartolini C; Molini MG; Di Lenarda A; Mazzone C; Scotti L; Lanati EP; Iorio A
J Cardiovasc Med (Hagerstown); 2019 Feb; 20(2):66-73. PubMed ID: 30540644
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness and Safety of Four Direct Oral Anticoagulants in Asian Patients With Nonvalvular Atrial Fibrillation.
Chan YH; Lee HF; See LC; Tu HT; Chao TF; Yeh YH; Wu LS; Kuo CT; Chang SH; Lip GYH
Chest; 2019 Sep; 156(3):529-543. PubMed ID: 31103697
[TBL] [Abstract][Full Text] [Related]
28. Comparative safety and effectiveness of dabigatran vs. rivaroxaban and apixaban in patients with non-valvular atrial fibrillation: a retrospective study from a large healthcare system.
Villines TC; Ahmad A; Petrini M; Tang W; Evans A; Rush T; Thompson D; Oh K; Schwartzman E
Eur Heart J Cardiovasc Pharmacother; 2019 Apr; 5(2):80-90. PubMed ID: 30500885
[TBL] [Abstract][Full Text] [Related]
29. Glycemic status and risks of thromboembolism and major bleeding in patients with atrial fibrillation.
Chan YH; Chuang C; Chan CC; Lee HF; Huang YC; Huang YT; Chang SH; Wang CL; Chao TF; Kuo CT; Yeh YH; Chen SA
Cardiovasc Diabetol; 2020 Mar; 19(1):30. PubMed ID: 32156277
[TBL] [Abstract][Full Text] [Related]
30. Long-Term Treatment with Apixaban in Patients with Atrial Fibrillation: Outcomes during the Open-Label Extension following AVERROES.
Benz AP; Eikelboom JW; Yusuf S; Hohnloser SH; Kahl A; Beresh H; Balasubramanian K; Healey JS; Connolly SJ
Thromb Haemost; 2021 Apr; 121(4):518-528. PubMed ID: 33011964
[TBL] [Abstract][Full Text] [Related]
31. Comparison of different direct oral anticoagulant regimens in atrial fibrillation patients with high bleeding risk.
Ciou WS; Wang CC; Lin FJ; Chao TF; Lin SY
Heart Rhythm; 2024 Jun; 21(6):715-722. PubMed ID: 38266751
[TBL] [Abstract][Full Text] [Related]
32. Clinical outcomes according to dose reduction criteria of apixaban in Japanese elderly patients with atrial fibrillation: J-ELD AF Registry subanalysis.
Akao M; Yamashita T; Suzuki S; Okumura K;
Heart Vessels; 2021 Jul; 36(7):1035-1046. PubMed ID: 33486555
[TBL] [Abstract][Full Text] [Related]
33. Apixaban versus Warfarin for the Prevention of Periprocedural Cerebral Thromboembolism in Atrial Fibrillation Ablation: Multicenter Prospective Randomized Study.
Kuwahara T; Abe M; Yamaki M; Fujieda H; Abe Y; Hashimoto K; Ishiba M; Sakai H; Hishikari K; Takigawa M; Okubo K; Takagi K; Tanaka Y; Nakajima J; Takahashi A
J Cardiovasc Electrophysiol; 2016 May; 27(5):549-54. PubMed ID: 26766541
[TBL] [Abstract][Full Text] [Related]
34. History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial.
De Caterina R; Andersson U; Alexander JH; Al-Khatib SM; Bahit MC; Goto S; Hanna M; Held C; Hohnloser S; Hylek EM; Lanas F; Lopes RD; López-Sendón J; Renda G; Horowitz J; Granger CB; Wallentin L;
Am Heart J; 2016 May; 175():175-83. PubMed ID: 27179738
[TBL] [Abstract][Full Text] [Related]
35. Low drug levels and thrombotic complications in high-risk atrial fibrillation patients treated with direct oral anticoagulants.
Testa S; Paoletti O; Legnani C; Dellanoce C; Antonucci E; Cosmi B; Pengo V; Poli D; Morandini R; Testa R; Tripodi A; Palareti G
J Thromb Haemost; 2018 May; 16(5):842-848. PubMed ID: 29532628
[TBL] [Abstract][Full Text] [Related]
36. Risk Levels and Adverse Clinical Outcomes Among Patients With Nonvalvular Atrial Fibrillation Receiving Oral Anticoagulants.
Lip GYH; Murphy RR; Sahiar F; Ingall TJ; Dhamane AD; Ferri M; Hlavacek P; Preib MT; Keshishian A; Russ C; Rosenblatt L; Yuce H; Deitelzweig S
JAMA Netw Open; 2022 Aug; 5(8):e2229333. PubMed ID: 36044214
[TBL] [Abstract][Full Text] [Related]
37. Safety and effectiveness of apixaban in comparison to warfarin in patients with nonvalvular atrial fibrillation: a propensity-matched analysis from Japanese administrative claims data.
Kohsaka S; Katada J; Saito K; Terayama Y
Curr Med Res Opin; 2018 Sep; 34(9):1627-1634. PubMed ID: 29772946
[TBL] [Abstract][Full Text] [Related]
38. Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.
Westenbrink BD; Alings M; Granger CB; Alexander JH; Lopes RD; Hylek EM; Thomas L; Wojdyla DM; Hanna M; Keltai M; Steg PG; De Caterina R; Wallentin L; van Gilst WH
Am Heart J; 2017 Mar; 185():140-149. PubMed ID: 28267467
[TBL] [Abstract][Full Text] [Related]
39. Bleeding rates of Veterans taking apixaban or rivaroxaban for atrial fibrillation or venous thromboembolism.
Howe Z; Naville-Cook C; Cole D
J Thromb Thrombolysis; 2019 Feb; 47(2):280-286. PubMed ID: 30449001
[TBL] [Abstract][Full Text] [Related]
40. Selecting the right anticoagulant for stroke prevention in atrial fibrillation.
Kundnani NR; Rosca CI; Sharma A; Tudor A; Rosca MS; Nisulescu DD; Branea HS; Mocanu V; Crisan DC; Buzas DR; Morariu S; Lighezan DF
Eur Rev Med Pharmacol Sci; 2021 Jul; 25(13):4499-4505. PubMed ID: 34286492
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
